Boston Scientific to Acquire Bolt Medical, Strengthening its Cardiovascular Portfolio
Shots:
- Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25
- Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to $221M regulatory milestones. (Deal is valued at $600M upfront & up to $300M milestones if the acquisition was for 100% stake)
- The Bolt IVL System uses lithotripsy to remove calcium in calcified lesions. The pivotal (RESTORE ATK & BTK) studies of Bolt IVL ATK & BTK Systems for PAD are completed, with data supporting the FDA’s approval & CE mark; another global FRACTURE IDE trial of Bolt IVL Coronary System for CAD has begun in Dec 2024
Ref: Boston Scientific | Image: Bolt Medical
Related News:- Boston Scientific Reports the Acquisition of Silk Road Medical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
